Press Release

<< Back
IRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting
The award winning CYCLO G6™ Glaucoma Laser System now offers a treatment with built-in transillumination

MOUNTAIN VIEW, Calif., Feb. 28, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) is pleased to announce the availability of the G-Probe™ Illuminate, a new, FDA-cleared probe offering combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC). The G-Probe Illuminate marks the third member of the family of probes powered by the CYCLO G6™ Glaucoma Laser System. This latest delivery device features built-in transillumination, which optimizes placement of the probe and therapeutic outcomes.

Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia and post-corneal transplants generate even more challenges. The G-Probe Illuminate allows physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.

"The visualization of the ciliary body and the surrounding area is impressive, allowing me to tailor the treatment to meet the needs of each of my patients," says leading glaucoma specialist Steven Vold, MD. "It has really helped me to deliver a targeted CPC treatment in an easy-to-use probe."

The G-Probe Illuminate may be utilized in the operating room or as an outpatient, office-based procedure providing a versatile option for treating glaucoma. "The prevalence of glaucoma is only increasing around the world, and Iridex is committed to improving and expanding the therapeutic options for both patients and surgeons. We look forward to introducing this new glaucoma device for ophthalmologists seeking better alternatives for treating glaucoma," says IRIDEX CEO, William Moore.

Frost & Sullivan recently awarded the CYCLO G6™ Laser System with the 2016 European New Product Innovation Award. Frost & Sullivan touted this system's ability to address various stages of glaucoma as well as a range of other unique benefits, such as the repeatability and non-incisional nature of the procedures.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning  future demand and order levels for the Company's products, future operating expenses, changes in personnel, product development and intellectual property related matters, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, the Company's future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2016, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-launches-new-fda-cleared-probe-at-the-annual-american-glaucoma-society-meeting-300414577.html

SOURCE IRIDEX Corporation

Media Contact: Jamie Hall, Pascale Communications, LLC., 724-417-0167, jamie@pascalecommunications.com or Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo, (415) 937-5404, investors@iridex.com



logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina